Jean Ge focuses on providing strategic intellectual property counsel to clients in the biotechnology and pharmaceutical spaces. Clients Jean represents range from venture-backed start-up companies and multinational pharmaceutical companies to financial institutions, such as private equity and venture capital firms, to research institutions. Jean partners with client teams to devise and implement an intellectual property strategy that furthers short- and long-term business goals. Jean advises clients in all areas of patent practice, including strategic patent portfolio development and management, worldwide patent prosecution, patent term adjustment and extension, patent landscape, freedom-to-operate studies, opinions, third party patent risk management strategies, conducting or defending IP due diligences in connection with investment or acquisition, and addressing IP issues in transactional matters. With nearly 10 years of research experience in the RNA field prior to joining Wolf Greenfield, Jean has a particular interest in RNA therapeutics. She works closely with clients in the RNA therapeutics space, including companies that develop RNA modalities ranging from siRNAs, gapmers, splicing switching antisense oligonucleotides, RNA editing oligonucleotides, CRISPR guide RNAs, tRNAs, RNA aptamers, mRNAs, circular RNAs, and antibody-oligonucleotide conjugates. With a deep appreciation of the opportunities and challenges in RNA research and drug development, Jean is uniquely positioned to serve clients in the RNA therapeutics field from technical, legal, regulatory, and business perspectives. Jean also has extensive experience in developing patent portfolios for protecting biologic therapeutics and in aligning patent strategies with regulatory strategies and product life cycle globally to provide strong exclusivity positions for clinical programs. She is an invited speaker at international conferences on patent strategies for complex biologic therapeutic molecules such as antibody-drug conjugates and antibody-oligonucleotide conjugates. Most recently, Jean was a panelist on a panel discussing IP space for antibody-drug conjugates (ADCs) at Biologics US 2024.